June 30th 2020, 5:01pm
Marwan G. Fakih, MD, discusses the June 2020 FDA approval of pembrolizumab for use in select patients with unresectable or metastatic solid tumors that are tumor mutational burden–high provides a potentially life-saving option to those who have exhausted all other available therapies.
June 29th 2020, 8:11pm
The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.
June 26th 2020, 2:12pm
Sylvia Adams, MD, discusses the cohort 36 findings of the DART trial in metaplastic breast cancer and the evolution of immunotherapy, specifically in this rare breast cancer subtype.
June 22nd 2020, 4:01am
The addition of the individualized neoantigen specific immunotherapy RO7198457 to atezolizumab induced neoantigen-specific T-cell responses, and was found to be well tolerated in patients with advanced solid malignancies.
June 18th 2020, 11:45am
The combination of atezolizumab and nab-paclitaxel, followed by doxorubicin and cyclophosphamide, demonstrated a statistically significant and clinically meaningful improvement in pathological complete response compared with placebo plus chemotherapy as a neoadjuvant treatment for patients with early triple-negative breast cancer, regardless of PD-L1 expression.
June 16th 2020, 9:44pm
Shilpa Gupta, MD, discusses the potential utility of neoadjuvant versus adjuvant immunotherapy in urothelial carcinoma.
June 16th 2020, 9:40pm
Andrew Coveler, MD, discusses the investigational CD40-directed monoclonal antibody SEA-CD40 in combination with gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma.
June 10th 2020, 3:17am
Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.
June 8th 2020, 8:51pm
Over the past decade, immunotherapy has established itself as one of the pillars of cancer treatment, thanks in large part to the success of monoclonal antibodies that target the immune checkpoint protein PD-1 or its main ligand, PD-L1.
June 8th 2020, 4:51pm
